Our Leadership

Our Leadership

Amerigen’s executive leadership is

made up of industry executives with decades of combined experience working for some of the most successful pharmaceutical enterprises in the world. At Amerigen, they’re putting their knowledge, experience, and expertise to work, providing quality medicines for a healthier world.

Partnering with Amerigen means having the security of knowing that your projects are in the care of experienced and knowledgeable industry veterans, directing a team of hardworking and dedicated professionals. Meet a few members of our Executive Management team below.

Executive Management


John W. Lowry, President & Chief Executive Officer
John Lowry was appointed President & CEO of Amerigen in 2010. Mr. Lowry has nearly 30 years of experience, most of which in leading product development organizations and global businesses in the pharmaceutical and medical device industries.

Most recently, Mr. Lowry was CEO of Catalent Pharma Solutions, a $1.7 billion leading provider of contract development, manufacturing and drug delivery technologies to global pharmaceutical and biotechnology customers. Prior to Catalent, he held several leadership positions for Cardinal Health, including Group President of Pharmaceutical Technologies and Services and President of R.P. Scherer. Mr. Lowry previously was President of Becton Dickinson’s Worldwide Diabetes Healthcare/Consumer Healthcare business and began his time at BD as Vice President of BD Medical Systems R&D.

Mr. Lowry spent the first 15 years of his career at GE, most recently at GE Healthcare. He holds a BSME from Villanova University.


Chief Financial Officer

Jonathan K. Embleton, Ph.D., Chief Business Officer
Jonathan Embleton was appointed Chief Business Officer for Amerigen in 2010. Dr. Embleton has 20 years of experience in R&D, project management, business development, strategy and licensing, with a particular focus on drug delivery technologies and generic products. Prior to joining Amerigen, he served as the Vice President for Product Ventures at Catalent Pharma Solutions, where he was also a member of the Executive Leadership Team.

Dr. Embleton was previously a vice-president working with generic pharmaceuticals for Cardinal Health, and earlier led the European business development and sales organization for Cardinal Health’s Pharmaceutical Technologies and Services business in Europe. Prior to that, Dr. Embleton held various product and technology development roles for RP Scherer Corporation.

Dr. Embleton earned a BSc in biochemistry and business administration, as well as a Ph.D in pharmaceutics, from the University of Aston in the UK.


Wenbin Dang, Ph.D., Senior Vice President, Product Development
Wenbin Dang was appointed Senior Vice President, Product Development, for Amerigen in 2010. Dr. Dang has 20 years of experience in pharmaceutical R&D, with a particular focus on drug delivery technologies and generic product development. Prior to joining Amerigen, she was Vice President, Product Development, at Catalent Pharma Solutions.

Prior to that, Dr. Dang worked for Cardinal Health’s Pharmaceutical and Technologies and Services business as Director of Formulation and Technology Development. She also held positions at Guilford Pharmaceuticals (now part of Eisai Pharmaceuticals) and Alkermes Inc. in various scientific and management roles.

Dr. Dang received her Ph.D. in Chemical Engineering from the Johns Hopkins University. She holds 13 US patents and is author of over twenty scientific journals and book chapters.


Oliver Mueller, President, Suzhou Pharma Services
Oliver Mueller was appointed President of Suzhou Pharma Services in 2012. Mr. Mueller has nearly 30 years of pharmaceutical industry experience, most of which include the effective implementation of new business ventures, corporate leadership and business development.

In his most recent positions, Mr. Mueller served as Executive Vice-President, Business Development and Executive Vice President, Glatt Pharmaceutical Services Division for Glatt Air Techniques, Inc., a premier provider of process technology, equipment and contract services for the development and manufacture of solid dosage drug products. Previously, Mr. Mueller held numerous other leadership positions at Glatt, including Vice President, Technology Sales & Services and Executive Vice President, Nortec Development Associates, a generic drug product out-licensing affiliate.

Prior to that, Mr. Mueller held positions at The Procter & Gamble Manufacturing Company and Merck & Company, Inc. He holds a B.S. Chemical Engineering degree from Lafayette College.


Joanne B. Marriott, Senior Vice President, Quality

Joanne B. Marriott was appointed Senior Vice President of Quality for Amerigen in November, 2011.  Ms. Marriott has over 35 years of experience in pharmaceutical Quality Assurance, Quality Control, Compliance and Regulatory Affairs with a focus on developing and maintaining quality systems in compliance with US FDA regulations.  Ms. Marriott also has experience with international pharmaceutical regulations having served in expatiate capacities in Quality Assurance and Compliance in Latin America and Europe.

Prior to joining Amerigen, Ms. Marriott was Vice President of Regulatory Affairs with Catalent Pharma Solutions and had previously served as Vice President Quality Assurance and Regulatory Affairs for Cardinal Health’s Pharmaceutical Development segment of the Pharmaceutical Technology and Services business.  Ms. Marriott also held positions at the Director level in both Quality Assurance and in Regulatory Affairs with Alcon Laboratories.  She holds a BS in Biology and an MA in Management and is Regulatory Affairs Certified (RAC) by the Regulatory Affairs Professionals Society.


David Quiggle, Vice President of Regulatory Affairs
David Quiggle was appointed Vice President, Regulatory Affairs, for Amerigen in October 2015. Mr. Quiggle has 20 years of pharmaceutical experience, with a focus on generic product development. Prior to joining Amerigen, he was Senior Director, Regulatory Affairs, at Anchen Pharmaceuticals (part of Par Pharmaceuticals).

Prior to that, Mr. Quiggle held positions at Watson Laboratories (now Actavis Inc.) and Encore Pharmaceuticals. He also worked at Loma Linda University in the School of Medicine performing preclinical drug development.

Mr. Quiggle received his Bachelors of Science and Masters of Science in Biology from the California State University.